Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial One randomized, double-blind, placebo-controlled trial evaluated the safety and effectiveness of oral semaglutide (GLP-1) 50 mg, taken once daily in adults with overweight or obesity who did not have type 2 diabetes
Be skeptical of any clinic that guarantees outcomes, prescribes without seeing you, or ships peptides from a research use only website
doi:10.1016/j.transproceed.2008.10.042
[PMID: 26863801] PubMed record related to this compound for laboratory literature review
Their primary hormonal action is on the somatotropic axis: more GH, more IGF-1, more protein synthesis, and more favorable partitioning between fat and lean mass
This was funded by Eli Lilly, India